Radioligand binding to brain dopamine and serotonin receptors and transporters in Parkinson's disease: Relation to gene polymorphisms

International Journal of Neuroscience

Volumn 122, Issue 3, 2012, Pages 124-132

  Güzey, Cüneyt ^a,b   Allard, Per ^c   Brännström, Thomas ^c   Spigset, Olav ^a,b  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c UMEÅ UNIVERSITY   (Sweden)

Author keywords

dopamine; genetics; Parkinson's disease; radioligand binding; receptor; serotonin

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; DOPAMINE TRANSPORTER; LEVODOPA; RADIOLIGAND; SEROTONIN 2A RECEPTOR; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER;

AGED; ARTICLE; AUTOPSY; BRAIN TISSUE; CAUDATE NUCLEUS; CINGULATE GYRUS; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIGAND BINDING; MALE; PARKINSON DISEASE; PROTEIN EXPRESSION; PUTAMEN; RADIOLIGAND BINDING;

AGED; AGED, 80 AND OVER; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; GENETIC TESTING; HUMANS; MALE; PARKINSON DISEASE; POLYMORPHISM, GENETIC; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 84856911179     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2011.631716     Document Type: Article

References (53)

1. Lang AE, Obeso JA. Challenges in Parkinsons disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol 2004;3:309-16.
2. Scatton B, Javoy-Agid F, Rouquier L,Dubois B, Agid Y. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinsons disease. Brain Res 1983;275:321-8.
3. Scholtissen B, Verhey FR, Steinbusch HW, Leentjens AF. Serotonergic mechanisms in Parkinsons disease: opposing results from preclinical and clinical data. J Neural Transm 2006;113:59-73.
4. Hurley MJ, Jenner P. What has been learnt from study of dopamine receptors in Parkinsons disease? Pharmaocl Ther 2006;111:715-28.
5. Brooks DJ, Pavese N. Imaging biomarkers in Parkinsons's disease. Progr Neurobiol Forthcoming 2011. DOI: 10.1016/j.pneurobio.2011.08.009.
6. Uhl GR. Dopamine transporter: basic science and human variation of a key molecule for dopaminergic function, locomotion, and parkinsonism. Mov Disord 2003;18 (Suppl. 7):S71-S80.
7. Vandenbergh DJ, Persico AM, Hawkins AL, Griffin CA, Li X, Jabs EW, Uhl GR. Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics 1992;14:1104-6.
8. Kim JW, Kim DH, Kim SH, Cha JK. Association of the dopamine transporter gene with Parkinsons disease in Korean patients. J Korean Med Sci 2000;15:449-5.
9. Le Couteur DG, Leighton PW, McCann SJ, Pond S. Association of a polymorphism in the dopamine-transporter gene with Parkinsons disease. Mov Disord 1997;12:760-3.
10. Lin JJ, YuehKC, ChangDC, ChangCY, Yeh YH, Lin SZ. The homozygote 10-copy genotype of variable number tandem repeat dopamine transporter gene may confer protection against Parkinsons disease formale, but not to female patients. J Neurol Sci 2003;209:87-92.
11. Noble EP, Blum K, Ritchie T, Montgomery A, Sheridan PJ. Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Arch Gen Psychiatry 1991;48:648-54.
12. Thompson J, Thomas N, Singleton A, Piggott M, Lloyd S, Perry EK, Morris CM, Perry RH, Ferrier IN, Court JA. D2 dopamine receptor gene (DRD2) Taq1A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 1997;7:479-84.
13. Grevle L, Guzey C, Hadidi H, Brennersted R, Idle JR, Aasly J. Allelic association between the DRD2 TaqI A polymorphism and Parkinsons disease. Mov Disord 2000;15:1070-4.
14. Rissling I,Geller F, Bandmann O, Stiasny-Kolster K, Korner Y, Meindorfner C, Kruger HP, Oertel WH,Moller JC. Dopamine receptor gene polymorphisms in Parkinsons disease patients reporting "sleep attacks". Mov Disord 2004;19:1279-84.
15. G̈uzey C, Scordo MG, Spina E, Landsem VM, Spigset O. Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms. Eur J Clin Pharmacol 2007;63:233-41.
16. Hedenmalm K, G̈uzey C, Dahl ML, Yue QY, Spigset O. Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms. J Clin Psychopharmacol 2006;26:192-7.
17. Chen CH, Wei FC, Koong FJ, Hsiao KJ. Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Biol Psychiatry 1997;41:827-9.
18. Jacobs BL, Fornal CA. Serotonin andmotor activity. Curr Opin Neurobiol 1997;7:820-5.
19. Hornykiewicz O. Biochemical aspects of Parkinsons disease. Neurology 1998;51 (suppl. 2):S2-S9.
20. Chen CP, Alder JT, Bray L, Kingsbury AE, Francis PT, Foster OJ. Post-synaptic 5-HT1A and 5-HT2A receptors are increased in Parkinsons disease neocortex. Ann N Y Acad Sci 1998;861:288-9.
21. Jellinger KA. Pathology of Parkinsons disease. Changes other than the nigrostriatal pathway. Mol Chem Neuropathol 1991;14:153-97.
22. Strecker K,Wegner F, Hesse S, Becker GA, Patt M, Meyer PM, Lobsien D, Schwarz J, Sabri O. Preserved serotonin transporter binding in de novo Parkinsons disease: negative correlation with the dopamine transporter. J Neurol 2011;258:19-26.
23. Guttman M, Boileau I,Warsh J, Saint-Cyr JA, Ginovart N,Mc- Cluskey T, Houle S, Wilson A, Mundo E, Rusjan P, Meyer J, Kish SJ. Brain serotonin transporter binding in non-depressed patients with Parkinsons disease. Eur J Neurol 2007;14:523-8.
24. Boileau I, Warsh JJ, Guttman M, Saint-Cyr JA, McCluskey T, Rusjan P, Houle S, Wilson AA, Meyer JH, Kish SJ. Elevated serotonin transporter binding in depressed patients with Parkinsons disease: a preliminary PET study with [11C]DASB. Mov Disord 2008;15:1776-80.
25. Ballanger B, Strafella AP, van Eimeren T, Zurowski M, Rusjan PM, Houle S, Fox SH. Serotonin 2A receptors and visual hallucinations in Parkonsin disease. Arch Neurol 2010;67: 416-21.
26. Lesch KP, Balling U, Gross J, Strauss K, Wolozin BL, MurphyDL, Riederer P. Organization of the human serotonin transporter gene. J Neural Transm Gen Sect 1994;95:157-62.
27. Heinz A, Jones DW, Mazzanti C, Goldman D, Ragan P, Hommer D, Linnoila M, Weinberger DR. A relationship between serotonin transporter genotype and in vivo protein expression and alcohol neurotoxicity. Biol Psychiatry 2000;47: 643-9.
28. Albani D, Vittori A, Batelli S, Polito L, De Mauro S, Galimberti D, Scarpini E, Lovati C, Mariani C, Forloni G. Serotonin transporter gene polymorphic element 5-HTTLPR increases the risk og sporadic Parkinsons disease in Italy. Eur Neurol 2009;62:120-3.
29. Menza MA, Palermo B, DiPaola R, Sage JI, Ricketts MH. Depression and anxiety in Parkinsons disease: possible effect of genetic variation in the serotonin transporter. J Geriatr Psychiatry Neurol 1999;12:49-52.
30. Mossner R, Henneberg A, Schmitt A, Syagailo YV, Grassle M, Hennig T, Simantov R, Gerlach M, Riederer P, Lesch KP. Allelic variation of serotonin transporter expression is associated with depression in Parkinsons disease. Mol Psychiatry 2001;6:350-2.
31. Burn DJ, Tiangyou W, Allcock LM, Davison J, Chinnery PF. Allelic variation of a functional polymorphism in the serotonin transporter gene and depression in Parkinsons disease. Parkinsonism Relat Disord 2006;12:139-41.
32. Zhang JL, Yang JF, Chan P. No association between polymorphism of the serotonin transporter gene and depression in Parkinsons disease in Chinese. Neurosci Lett 2009;455: 155-8.
33. Polesskaya OO, Sokolov BP. Differential expression of the "C" and "T" alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenics. J Neurosci Res 2002;67:812-22.
34. Lerer B, Segman RH,Tan EC, Basile VS,Cavallaro R, Aschauer HN, Strous R, Chong SA, Heresco-Levy U, Verga M, Scharfetter J, Meltzer HY, Kennedy JL, Macciardi F. Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype. Int J Neuropsychopharmacol 2005;8:411-25.
35. Hazelwood LA, Sanders-Bush E. His452Tyr polymorphism in the human 5-HT2A receptor destabilizes the signaling conformation. Mol Pharmacol 2004;66:1293-300.
36. Segman RH, Goltser T, Heresco-Levy U, Finkel B, Shalem R, Schlafman M, Yakir A, Greenberg D, Strous R, Lerner A, Shelevoy A, Lerer B. Association of dopaminergic and serotonergic genes with tardive dyskinesia in patients with chronic schizophrenia. Pharmacogenomics J 2003;3:277-83.
37. Allard P, Englund E, Marcusson J. Reduced number of caudate nucleus dopamine uptake sites in vascular dementia. Dement Geriatr Cogn Disord 1999;10:77-80.
38. Hall H, Farde L, Sedvall G. Human dopamine receptor subtypes-in vitro binding analysis using 3H-SCH 23390 and 3H-raclopride. J Neural Transm 1988;73:7-21.
39. Arranz B, Marcusson J. [3H]paroxetine and [3H]citalopram as markers of the human brain 5-HT uptake site: A comparison study. J Neural Transm Gen Sect 1994;97:27-40.
40. B̈ackstr̈om I, Bergstr̈om M, Marcusson J. High affinity [3H]paroxetine binding to serotonin uptake sites in human brain tissue. Brain Res 1989;486:261-8.
41. Rosel P, Arranz B, Vallejo J, Oros M, Crespo JM,Menchon JM, Navarro MA. Variations in [3H]imipramine and 5-HT2A but not [3H]paroxetine binding sites in suicide brains. Psychiatry Res 1998;82:161-70.
42. Markwell MA, Haas SM, Bieber LL, Tolbert NE. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem 1978;87: 206-10.
43. Grandy DK, Litt M, Allen L, Bunzow JR, Marchionni M, Makam H, Reed L, Magenis RE, Civelli O. The human dopamine D2 receptor gene is located on chromosome 11 at q22-q23 and identifies a TaqI RFLP. Am J Hum Genet 1989;45:778-85.
44. Lannfelt L, SokoloffMPP, Pilon C, Giros B, Jonsson E, Sedvall G, Schwartz J. Amino acid substitution in the dopamine D3 receptor as a useful polymorphism for investigation psychiatric disorders. Psychiatric Gen 1992;2:249-56.
45. Steen VM, Løvlie R, MacEwan T, McCreadie RG. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry 1997;2:139-45.
46. Gelernter J, Kranzler H, Cubells JF. Serotonin transporter protein (SLC6A4) allele and haplotype frequencies and linkage disequilibria in African- and European-American and Japanese populations and in alcohol-dependent subjects. Hum Genet 1997;101:243-6.
47. Erdmann J, Shimron-Abarbanell D, Rietschel M, Albus M, Maier W, Korner J, Bondy B, Chen K, Shih JC, Knapp M, Propping P, Nothen MM. Systematic screening for mutations in the human serotonin-2A (5-HT2A) receptor gene: identification of two naturally occurring receptor variants and association analysis in schizophrenia. Hum Genet 1996;97:614-9.
48. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinsons disease: pathophysiologic and clinical implications.NEngl J Med 1988;318:876-80.
49. Morrish PK, SawleGV, BrooksDJ. Clinical and [18F]dopa PET findings in early Parkinsons disease. J Neurol Neurosurg Psychiatry 1995;59:597-600.
50. Mill J, Asherson P, Craig I, D'Souza UM. Transient expression analysis of allelic variants of a VNTR in the dopamine transporter gene (DAT1). BMC Genet 2005;6:3.
51. Fuke S, Suo S, Takahashi N, Koike H, Sasagawa N, Ishiura S. The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression. Pharmacogenomics J 2001;1:152-6.
52. Greenwood TA, Kelsoe JR. Promoter and intronic variants affect the transcriptional regulation of the human dopamine transporter gene. Genomics 2003;82:511-20.
53. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinsons disease: A clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.